Evidence map›Paper›PMID 42359755›Full record

ArticleRadiology and oncology2026

Genetic variability of immune checkpoints in asbestos-related diseases.

Irma Zeljkovic, Katja Goricar, Tanja Blagus, Alenka Franko, Viljem Kovac, Vita Dolzan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Irma Zeljkovic1Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia.
Katja Goricar3Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Tanja Blagus3Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Alenka Franko4Clinical Institute of Occupational Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Viljem Kovac5Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Vita Dolzan3Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAsbestos exposure is associated with asbestos-related diseases such as pleural plaques, asbestosis, lung cancer, malignant mesothelioma (MM), as well as several other types of cancer. Although the exact mechanism underlying the development of asbestos-related diseases is not yet fully understood, the immune system may play an important role. Immune checkpoints such as programmed cell death receptor 1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) regulate immune responses and are crucial for maintaining immune tolerance, while defects in these mechanisms can lead to the development of cancer. The aim of present study was to investigate the association of polymorphisms in the immune checkpoint genes for PD-1 ( SUBJECTS AND

methodsWe conducted a retrospective case-control study. The cases included individuals with asbestosis or pleural plaques and MM patients. The controls were asbestos-exposed subjects who did not develop asbestos-related diseases. All subjects were genotyped for

resultsOur study showed that the

conclusions

Indexed as

AsbestosisB7-H1 AntigenCTLA-4 AntigenLung NeoplasmsMesotheliomaProgrammed Cell Death 1 ReceptorAgedAsbestosCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMesothelioma, MalignantMiddle AgedAsbestosB7-H1 AntigenCD274 protein, humanCTLA-4 AntigenCTLA4 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 Receptorasbestosimmune checkpointsmalignant mesotheliomasingle nucleotide polymorphism

Identifiers

PMID42359755
PMCPMC13307012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.